Ligilactobacillus salivarius H22A013

Ligilactobacillus salivarius H22A013 is an investigational native probiotic strain being studied for the treatment of melanoma. [1, 2, 3] It is administered directly into the tumor with the goal of remodeling the tumor microenvironment (TME). [1, 2] Research has shown that when combined with the targeted therapy trametinib, L. salivarius H22A013 increased the levels of immune-stimulating cytokines IFN-γ and TNF-α, which in turn enhanced the infiltration of immune cells and amplified the body's anti-tumor immune response. [1, 2] Furthermore, the strain was observed to migrate from the tumor to the gut, where it altered the composition and metabolic activity of the gut microbiota. This led to the suppression of spermine/spermidine degradation and an increase in valine synthesis, contributing to a systemic tumor suppression effect. [1] This dual-action approach, both local within the tumor and systemic via the gut, represents a novel strategy in cancer therapy using native probiotics. The research was published in BMC Microbiology in January 2026. [1, 2, 3] The developing entity is not specified in the available information, and the agent does not yet have a brand name.